Keywords: Castration-resistant prostate cancer; AR splice variants; AR-V7; Circulating tumour DNA; Structural variation; Endocrine treatment; Androgen receptor;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: aCGH; array-comparative genomic hybridization; AR; androgen receptor; AR-V7; AR splice variant 7 messenger RNA; ASGR1; asialoglycoprotein receptor; BMDC; bone marrow-derived cells; CDH1; Cadherin 1; CDH2; Cadherin 2, type 1, N-cadherin (neuronal); cfDNA
Keywords: Prostate cancer; Androgen receptor; AR-V7; Biomarker; CRPC;
Keywords: aCGH; array comparative genomic hybridization; ADT; androgen deprivation therapy; AR; androgen receptor; AR-V7; androgen receptor splice variant 7; CI; confidence interval; CK; cytokeratin; CT; computed tomography; CTC; circulating tumor cell; EGFR; epide
Keywords: Androgen receptor; Prostate cancer; AR-V7; Pharmacology; Mutation;
Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer
Keywords: Androgen receptor; RNA in situ hybridization; Splice variant; AR-V7;
Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy
Keywords: Prostate cancer; Androgen receptor; AR-V7; Adjuvant therapy;
A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer
Keywords: Enzalutamide; Prostate; Cancer; Therapeutic drug monitoring; HPLC-UV; AR-V7; androgen receptor splice variant-7; Ctrough; steady-state trough plasma concentration; CV; coefficient of variation; CYP; cytochrome P450; DMSO; dimethylsulfoxide; EMA; European
The RNA helicase DDX39B and its paralog DDX39A regulate androgen receptor splice variant AR-V7 generation
Keywords: AR-V7; DDX39B; UAP56; DDX39A; URH49; Castration-resistant prostate cancer; AR; androgen receptor; AR-FL; full-length AR; ADT; androgen deprivation therapy; CRPC; castration-resistant prostate cancer; DEG; differentially-expressed genes; FBS; fetal bovine
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients
Keywords: AR-V7; Exosomes; Digital droplet PCR; Prostate cancer; Pharmacogenetics; Resistance; Hormonal therapy;
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer
Keywords: AR-V7; Circulating tumor cells; Liquid biopsy; Prostate cancer;
Hot TopicMechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer
Keywords: Prostate cancer; Resistance; Taxane; AR-targeted agent; Biomarker; AR-V7; ERG;
AR-V7 and prostate cancer: The watershed for treatment selection?
Keywords: Prostate cancer; Androgen receptor; Splice variant; AR-V7; Prognostic role; Anti-androgens sensitivity; Taxane sensitivity
Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
Keywords: ADT; androgen deprivation therapy; AR; androgen receptor; AR-V; androgen receptor splice variant; AR-V7; androgen receptor splice variant 7; ASCO; American Society of Clinical Oncology; CRPC; castration-resistant prostate cancer; CTC; circulating tumor ce
Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells
Keywords: AR-V7; Androgen receptor; Cabazitaxel; Castration-resistant prostate cancer; CellSearch; Circulating tumor cells; Metastatic prostate cancer